These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35643116)
21. Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV Nagy B; Bene Z; Fejes Z; Heltshe SL; Reid D; Ronan NJ; McCarthy Y; Smith D; Nagy A; Joseloff E; Balla G; Kappelmayer J; Macek M; Bell SC; Plant BJ; Amaral MD; Balogh I J Cyst Fibros; 2019 Mar; 18(2):271-277. PubMed ID: 30268371 [TBL] [Abstract][Full Text] [Related]
22. Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry. Kawala CR; Ma X; Sykes J; Stanojevic S; Coriati A; Stephenson AL J Cyst Fibros; 2021 Nov; 20(6):1040-1045. PubMed ID: 33810992 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M; Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913 [TBL] [Abstract][Full Text] [Related]
24. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis. Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367 [TBL] [Abstract][Full Text] [Related]
26. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations. Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA; Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085 [TBL] [Abstract][Full Text] [Related]
29. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026 [No Abstract] [Full Text] [Related]
30. Factors indicative of long-term survival after lung transplantation: a review of 836 10-year survivors. Weiss ES; Allen JG; Merlo CA; Conte JV; Shah AS J Heart Lung Transplant; 2010 Mar; 29(3):240-6. PubMed ID: 19932034 [TBL] [Abstract][Full Text] [Related]
31. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. Dilokthornsakul P; Hansen RN; Campbell JD Eur Respir J; 2016 Jun; 47(6):1697-705. PubMed ID: 27126691 [TBL] [Abstract][Full Text] [Related]
32. Clinical Outcomes and Prognostic Factors in a Cohort of Adults With Cystic Fibrosis: A 7-Year Follow-Up Study. Flores JS; Rovedder PM; Ziegler B; Pinotti AF; Barreto SS; Dalcin Pde T Respir Care; 2016 Feb; 61(2):192-9. PubMed ID: 26715773 [TBL] [Abstract][Full Text] [Related]
33. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW; Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234 [TBL] [Abstract][Full Text] [Related]
34. Pre-transplant factors associated with mortality after lung transplantation in cystic fibrosis: A systematic review and meta-analysis. Koutsokera A; Varughese RA; Sykes J; Orchanian-Cheff A; Shah PS; Chaparro C; Tullis E; Singer LG; Stephenson AL J Cyst Fibros; 2019 May; 18(3):407-415. PubMed ID: 30482682 [TBL] [Abstract][Full Text] [Related]
35. Age-related survival disparity associated with lung transplantation in cystic fibrosis: An analysis of the registry of the International Society for Heart and Lung Transplantation. Hayes D; Glanville AR; McGiffin D; Tobias JD; Tumin D J Heart Lung Transplant; 2016 Sep; 35(9):1108-15. PubMed ID: 27296835 [TBL] [Abstract][Full Text] [Related]
36. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation]. Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322 [TBL] [Abstract][Full Text] [Related]
38. Association of Oxygen Therapy with the Natural Disease Progression of Cystic Fibrosis: A Multi-State Model of the European Cystic Fibrosis Society Patient Registry. Gambazza S; Orenti A; Pizzamiglio G; Zolin A; Colombo C; Laquintana D; Ambrogi F; Ther Clin Risk Manag; 2023; 19():255-267. PubMed ID: 36935771 [TBL] [Abstract][Full Text] [Related]